linjc16/ctgov huggingface dataset:
The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy

Study Overview
=================
Brief Summary
-----------------
As the duration of the interval between the time of last preparation-agent dose and the start of the colonoscopy is increasing, the quality of bowel preparation will be worse.

Detailed Description
-----------------
The aim of the present studies is to determine how the duration of the interval of the time of last preparation dose and the start of colonoscopy affects the quality of the bowel preparation and when the proper timing of the colonoscopy is after completion of last preparation regimen

Official Title
-----------------
The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy

Conditions
-----------------
The Timing of Bowel Preparation in Outpatient Colonoscopy

Intervention / Treatment
-----------------
* Drug: bowel preparation using split dose of polyethylene glycol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult outpatients(18-85 years of age) who undergo colonoscopy for screening, cancer surveillance or with gastrointestinal symptoms, other symptoms Exclusion Criteria: age under 18 years, pregnancy, breast feeding, prior history of surgical large bowel resection, severe renal failure (creatinine ≥ 3.0mg/dL (normal 0.8-1.4)), drug addiction or major psychiatric illness; allergy to PEG, refusal of consent to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| outpatient colonoscopy, bowel preparation, split dose PEG<br>adult outpatients who undergo colonoscopy | Drug: bowel preparation using split dose of polyethylene glycol<br>* polyethylene glycol, split dose(2L/2L), each dose for 1-2hours<br>* Other names: Colyte;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of bowel preparation according to Ottawa scale | The primary end point of the study was to assess the quality of bowel preparation according to the Ottawa scale, including cleanliness and fluid quantity. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proper timing of colonoscopy | The secondary end points was to determine the proper interval between the completion of spliting bowel preparation and the start of colonoscopy. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bowel preparation, Polyethylene glycols, Colonoscopy, Outpatient
Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants

Study Overview
=================
Brief Summary
-----------------
Many patients suffer from devastating injuries to vascularized composite tissues. Vascularized composite tissues are blocs of functional tissue that can contain multiple tissue types such as bone, muscle, nerves, blood vessels, tendons, ligaments, and others. Examples of patients with severe vascularized composite tissue defects include limb amputees, patients with third-degree burns to the face or extremities, soldiers with improvised-explosive-device blast injuries to the face, and others. These patients cannot be helped satisfactorily with conventional reconstructive surgery; however, recently vascularized composite allotransplantation (VCA) such as transplantation of faces and limbs became available to this patients. Unfortunately, at this juncture, patients who receive VCA must submit to life-long regime of immunosuppressant drugs with serious side effects such as infection, renal toxicity and cancer. Immune tolerance is the absence of a destructive immune response from the recipient's body to the transplant, while otherwise maintaining sufficient immune function to fight infections and other threats. Transplant recipients with immune tolerance do not need to take immunosuppression drugs. The investigators believe that they can achieve immune tolerance in recipients of face and limb transplants.

Official Title
-----------------
Biomarker-guided Withdrawal of Immunosuppression in Recipients of Vascularized Composite Tissue Transplants

Conditions
-----------------
Vascularized Composite Allotransplantation

Intervention / Treatment
-----------------
* Biological: Interleukin-2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults who have received VCA transplants at Brigham and Women's Hospital no less than 3 months elapsed since VCA transplant, on steroid-free immune dual immunosuppression with tacrolimus (6-8 ng/ml trough levels) and mycophenolate mofetil, no current concerns of rejection Exclusion Criteria: recent (<3 months) episodes of rejection, active bacterial or viral infection, malignancy, non-healing wounds pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interleukin 2<br>Subjects who receive a tolerogenic drug protocol | Biological: Interleukin-2<br> <br> * Other names: Aldesleukin, proleukin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete cessation of immune suppression without evidence of rejection for more than 6 months. |  | 6 -24 months |
Core Temperature in Patients With OHCA

Study Overview
=================
Brief Summary
-----------------
A prospective observational study aiming to monitor core temperature via an esophageal probe in out of hospital cardiac arrest during transport and until arrival in hospital. Insertion of an esophageal temperature probe will be done on scene during ongoing resuscitation manoeuvres based on European Resuscitation Council Guidelines 2015 (or newer). Environmental temperature influence and hypothermia prevention interventions will be monitored.

Detailed Description
-----------------
Prospective observational study to evaluate the body temperature difference in patients in out of hospital cardiac arrest on site and at arrival at the hospital. If the patient fulfills the inclusion criteria and after establishment of CPR measures according the ERC resuscitation guidelines (2015 or newer) an esophageal probe will be inserted and bodytemperature is measured; on site ambiental temperature will also be measured. Weather conditions, altitude on site, activity of the patient and hypothermia protection (eg. clothes) will bei documented. On arrival in hospital the body temperature will be measured with the esophageal probe;

Official Title
-----------------
Core Temperature in Patients With Out of Hospital Cardiac Arrest in South Tyrol - a Prospective Observational Study

Conditions
-----------------
Out-Of-Hospital Cardiac Arrest, Accidental Hypothermia, Temperature Change, Body

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Out of hospital cardiac arrest Patients transferred to hospital > 18 years Exclusion Criteria: Obvious signs of death Obvious lethal injury/injuries incompatible with life Confirmation of death on scene < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Core temperature at hospital arrival | ° Celsius | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Core temperature at ROSC | ° Celsius | through study completion, an average of 1 year | 
| Environmental temperature on scene | ° Celsius | through study completion, an average of 1 year | 
| Time of resuscitation from OHCA to ROSC | minutes | through study completion, an average of 1 year | 
| OHCA rhythm at arrival of ALS team | ECG rhythm: asystolia, PEA, ventricular fibrillation, ventricular tachicardia | through study completion, an average of 1 year | 
| Use of mechanical chest compression device on prehospital intervention |  | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Out-Of-Hospital Cardiac Arrest, Accidental Hypothermia, Core Temperature
Genomic Study of Congenital Malformation

Study Overview
=================
Brief Summary
-----------------
Genomic aberrations in patients diagnosed as congenital malformation with unknown etiology will be identified using high-density oligonucleotide array.

Detailed Description
-----------------
The Affymetrix GeneChip® Human Mapping SNP 6.0 array, includes more than 900,000 SNP probes plus more than 900,000 CNV probes in a single chip, can provide high density makers information for the human genome. The median inter-marker distance is 670 bases and the average inter-marker distance is 1.67 kb, and the resolution can be as high as 200 kb. The Affymetrix® Cytogenetics Whole-Genome 2.7M Array gives the greatest power to detect known and novel chromosome aberrations across the entire genome. In addition, the whole-genome array includes 400,000 single nucleotide polymorphisms (SNPs) to enable the detection of loss of heterozygosity (LOH), uniparental disomy (UPD), and regions identical-by-descent. If we are able to identify the candidate genomic regions that are associated with the congenital malformation/syndrome, we may have a better chance to understand the pathogenesis of congenital malformation/syndrome as well as the mechanisms underlying the abnormal chromosome rare diseases. The results from this study can also facilitate the clinical diagnosis and provide genetic basis for consultation.

Official Title
-----------------
Genomic Study of Congenital Malformation

Conditions
-----------------
Genomic Aberrations in Patients Diagnosed as Congenital Malformation With Unknown Etiology

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is diagnosed as congenital malformation/syndromes. Participants can be any ages, and both males and females are eligible. Subjects agree and are capable of giving informed consent. If participants are under 18 years old or incapable of giving consent, an informed consent must be approved by their legal guardians. Availability and willingness of the proband and first-degree biological family (parents, full sibling, or adult-age offspring) who also meets the same congenital malformation syndrome. Availability and willingness of the proband's biological parents whatever with or without the same congenital malformation syndrome. Exclusion Criteria: Subject or legal guardian is unable to understand or give informed consent. The molecular cause for congenital malformation/syndromes of subjects or their affected first-degree biological family (parents, full sibling, or adult-age offspring) can be revealed by karyotype assay or FISH.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Pilot Study to Test the Acceptability and Feasibility of Relaxation Rooms to Help Reduce Occupational Stress Among Healthcare Workers

Study Overview
=================
Brief Summary
-----------------
Test the acceptability and feasibility of a relaxation room to reduce work stress among clinicians and collect clinician-reported outcome data after using the relaxation room.

Detailed Description
-----------------
The plan is to pilot test a relaxation room to demonstrate its acceptability and feasibility in the hospital and collect clinician-centered outcomes. This study will inform the design of a future trial using this intervention.

Official Title
-----------------
A Pilot Study to Test the Acceptability and Feasibility of Relaxation Rooms to Help Reduce Occupational Stress Among Healthcare Workers

Conditions
-----------------
Burn Out, Stress

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinician at Mayo working at St. Mary's hospital or the downtown Rochester campus during the study Exclusion Criteria: Any physical condition that might prevent them from sitting for 20-30 minutes in the room Significant hearing loss that they would not be able to hear the audio stimuli Significant vision loss that they would not be able to see the visual stimuli

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acceptability | the proportion of clinicians who found the MindBreaks room to be somewhat acceptable or acceptable | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recruitment | the number recruited | 12 months | 
| Room Usage | how long participants stayed in the MindBreaks room | 12 months |
Postoperative Delirium in Hip Fracture Patients

Study Overview
=================
Brief Summary
-----------------
Risk factors for postoperative delirium in hip fracture patients.

Official Title
-----------------
Postoperative Delirium in Hip Fracture Patients

Conditions
-----------------
Delirium

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hip fracture age 65 or older Exclusion Criteria: critical ill/ dying aphasia

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delirium/ no-delirium |  | 5 days postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of delirium, length of delirium, complications, comorbidity, one-year mortality. |  | 5 days postoperative, one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
delirium, pathophysiology, risk factors, pain, dementia
Intravenous Iron in Patients With Anemia of Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
The objective of this study is the evaluation of the efficacy and safety of intravenous iron sucrose in anemic patients with chronic kidney disease not on renal replacement therapy.

Detailed Description
-----------------
This is a randomized, open label, phase IV study in anemic predialysis patients (Hb between 8 and 11.5 g/dl) who require iron supplementation. The duration of the study for each patient will be approximately 6 months. Patients will be randomized to one of two treatment arms and admitted to the anemia correction phase (days 1-43). Treatment will be intravenous iron sucrose alone versus iron sucrose plus rhEPO. The main treatment evaluation will at the end of the correction phase: The primary end-point will be the change of hemoglobin during correction phase. Secondary end-points will be the change of ferritin and transferrin saturation from baseline to day 43. Safety assessments will include recording of adverse events, vital signs, physical examinations and clinical laboratory tests. Incidence and severity of adverse events will be compared between the two different treatment arms.

Official Title
-----------------
Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease

Conditions
-----------------
Kidney Failure, Chronic

Intervention / Treatment
-----------------
* Drug: Iron sucrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic kidney disease Anemia (Hb 8 - 11.5 g/dl) Age above 18 years Signed informed consent Exclusion Criteria: Rapid progression of kidney disease Need for dialysis Uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Iron sucrose|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in hemoglobin from baseline to day 43 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in ferritin and transferrin saturation from baseline to day 43; incidence and severity of adverse events |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic kidney disease, anemia, intravenous iron, recombinant human erythropoetin
Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate markers of immune response in human tumor samples.

Detailed Description
-----------------
Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective in most patients. The reason for this inconsistency, and the conditions necessary for successful immunotherapy, are not well understood. Our studies in animal tumor models indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma expression in tumor indicate such an immune response. We therefore plan to evaluate the existing immune response in human tumor samples in an effort to identify those patients most likely to respond to therapy with IL-12.

Official Title
-----------------
Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Any adult patient with a tumor who is scheduled to undergo surgery to either remove or biopsy the tumor. Exclusion Criteria:Patients without tumor and pediatric patients (children) will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Can Parental Activation Over the Internet Improve Pediatric Preventive Care?

Study Overview
=================
Brief Summary
-----------------
This study is a randomized controlled trial of an evidence based, patient specific web site's ability to improve preventive practices in pediatric care. Parents visit the website within 2 weeks of a scheduled well child visit and are presented with a menu of age specific topics that they can read about as they wish.

Official Title
-----------------
Parent Initiated Prevention Program

Conditions
-----------------
Well Child Preventive Care

Intervention / Treatment
-----------------
* Procedure: An evidence based tailored web site


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: <11 years Exclusion Criteria: Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: An evidence based tailored web site|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention Practices |  |  | 
| Satisfaction with care |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prevention, internet, quality of care